| HOME >> MEDICINE >> TECHNOLOGY |
Table 5.15 Dainippon Sumitomo: Key Facts, 2012
Table 5.16 Dainippon Sumitomo: Antibacterial Revenue, FY 2009-2011
Table 5.17 Dainippon Sumitomo: Antibacterial SWOT Analysis, 2012-2022
Table 5.18 Dainippon Sumitomo: Antibacterial Revenue Forecast, 2011-2022
Table 6.1 Cubist Pharmaceuticals: Key Facts, 2012
Table 6.2 Cubist: Antibacterial Revenue, 2008-2011
Table 6.3 Cubicin: International Revenue Payments, 2008-2011
Table 6.4 Cubist: Antibacterial SWOT Analysis, 2012-2022
Table 6.5 Cubist: Antibacterial Revenue Forecast, 2011-2022
Table 6.6 Medicis: Key Facts, 2012
Table 6.7 Medicis: Antibacterial Revenue, 2009-2011
Table 6.8 Medicis: Antibacterial SWOT Analysis, 2012-2022
Table 6.9 Medicis: Antibacterial Revenue Forecast, 2011-2022
Table 6.10 Salix Pharmaceuticals: Key Facts, 2012
Table 6.11 Salix: Antibacterial Revenue, 2009-2011
Table 6.12 Salix: Antibacterial SWOT Analysis, 2012-2022
Table 6.13 Salix: Antibacterial Revenue Forecast, 2011-2022
Table 6.14 ViroPharma: Key Facts, 2012
Table 6.15 ViroPharma: Antibacterial Revenue, 2009-2011
Table 6.16 ViroPharma: Antibacterial SWOT Analysis, 2012-2022
Table 6.17 ViroPharma: Antibacterial Revenue Forecast, 2011-2022
Table 6.18 Warner Chilcott: Key Facts, 2012
Table 6.19 Warner Chilcott: Antibacterial SWOT Analysis, 2012-2022
Table 6.20 Warner Chilcott: Antibacterial Revenue Forecast, 2011-2022
Table 6.21 Allergan: Key Facts, 2012
Table 6.22 Allergan: Antibacterial SWOT Analysis, 2012-2022
Table 6.23 Allergan: Antibacterial Revenue Forecast, 2011-2022
Table 7.1 Emerging Companies in the Antibacterial Drugs Market, 2012
Table 8.1 Top 20 Antibacterial Manufacturers by Company Type, 2011
List of Figures Figure 2.1 Antibacterial Drugs Market by Class, 2010-2011Figure 2.2 Antibacterial Drugs
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |